ES2687651T3 - Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos - Google Patents

Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos Download PDF

Info

Publication number
ES2687651T3
ES2687651T3 ES12831010T ES12831010T ES2687651T3 ES 2687651 T3 ES2687651 T3 ES 2687651T3 ES 12831010 T ES12831010 T ES 12831010T ES 12831010 T ES12831010 T ES 12831010T ES 2687651 T3 ES2687651 T3 ES 2687651T3
Authority
ES
Spain
Prior art keywords
glucagon
xten
sequence
glp
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12831010T
Other languages
English (en)
Inventor
Volker Schellenberger
Joshua Silverman
Willem P. Stemmer
Chia-Wei Wang
Nathan Geething
Benjamin Spink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Application granted granted Critical
Publication of ES2687651T3 publication Critical patent/ES2687651T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Una composición para su uso en el tratamiento de la enteritis en un sujeto mamífero logrando un efecto intestinotrófico, comprendiendo la composición una proteína de fusión que comprende: (i) una secuencia de proteína-2 similar a glucagón (GLP-2) que consiste en la secuencia: HGDGSFSDEMNTILDNLAARDFINWLIQTKITD y (ii) un polipéptido recombinante extendido (XTEN), en donde el XTEN es la secuencia AE864 de la tabla 4; en donde dicha composición muestra un efecto intestinotrófico cuando se administra al sujeto con enteritis que es al menos un 100% o al menos un 120% o al menos un 150% o al menos un 200% del efecto intestinotrófico comparado con el GLP-2 correspondiente no unido a XTEN tras la administración de dicho GLP-2 correspondiente a un sujeto comparable usando una dosis comparable.
ES12831010T 2011-09-12 2012-09-12 Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos Active ES2687651T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161573748P 2011-09-12 2011-09-12
PCT/US2012/054941 WO2013040093A2 (en) 2011-09-12 2012-09-12 Glucagon-like peptide-2 compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
ES2687651T3 true ES2687651T3 (es) 2018-10-26

Family

ID=47883955

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12831010T Active ES2687651T3 (es) 2011-09-12 2012-09-12 Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos

Country Status (12)

Country Link
US (3) US20160137711A1 (es)
EP (2) EP3431098A1 (es)
JP (2) JP6206972B2 (es)
KR (1) KR102007054B1 (es)
CN (1) CN103945861B (es)
AU (2) AU2012308636B2 (es)
BR (1) BR112014005744B1 (es)
CA (1) CA2848204C (es)
DK (1) DK2755675T3 (es)
ES (1) ES2687651T3 (es)
PT (1) PT2755675T (es)
WO (1) WO2013040093A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
IL307276A (en) 2015-08-28 2023-11-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CN105602877B (zh) * 2016-01-25 2019-02-01 广州沃德生物技术有限公司 一种定点改造的猪源glp-2重组植物乳杆菌及其制备方法和应用
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
CA3066523A1 (en) * 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CA3071966A1 (en) * 2017-08-22 2019-02-28 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
JP7095078B2 (ja) * 2017-09-22 2022-07-04 カイト ファーマ インコーポレイテッド キメラポリペプチド及びその使用
TWI794897B (zh) * 2017-09-28 2023-03-01 南韓商韓美藥品股份有限公司 Ｇｌｐ-２衍生物之長效接合物
JP7296958B2 (ja) 2017-11-06 2023-06-23 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ
US11267863B2 (en) 2018-01-19 2022-03-08 Pepgene Inc. N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same
JP7238715B2 (ja) 2018-09-19 2023-03-14 東洋インキＳｃホールディングス株式会社 水性グラビアまたはフレキソインキ、印刷物および積層体
CN110305223B (zh) 2019-06-26 2022-05-13 重庆派金生物科技有限公司 重组串联融合蛋白制备目标多肽的方法
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
CN114213524A (zh) * 2021-11-08 2022-03-22 苏州博领干细胞再生医学有限公司 用于胰高血糖素样肽-2抗体检测的包被抗原及纯化方法、重组工程菌及培养方法
WO2024018037A1 (en) * 2022-07-20 2024-01-25 Bioinnova S.R.L.S. Microalgae expressing glp-2 and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4885249A (en) 1984-12-05 1989-12-05 Allelix, Inc. Aspergillus niger transformation system
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AT387234B (de) 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) * 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
ES2361095T5 (es) 2005-05-04 2021-11-23 Zealand Pharma As Análogos del péptido 2 tipo glucagón (GLP-2)
WO2007074010A1 (en) * 2005-12-24 2007-07-05 Teagasc Dairy Products Research Centre Process for the production of trans-10, cis 12 octadecadienoic acid
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CN102348715B (zh) * 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2010290077C1 (en) * 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド

Also Published As

Publication number Publication date
EP3431098A1 (en) 2019-01-23
JP2014526254A (ja) 2014-10-06
JP6206972B2 (ja) 2017-10-04
CA2848204C (en) 2023-04-04
AU2017268558A1 (en) 2017-12-21
US20160137711A1 (en) 2016-05-19
KR20140069131A (ko) 2014-06-09
JP2017186374A (ja) 2017-10-12
AU2012308636A1 (en) 2014-03-27
DK2755675T3 (en) 2018-08-06
EP2755675B1 (en) 2018-06-06
BR112014005744B1 (pt) 2020-11-17
BR112014005744A2 (pt) 2017-03-28
PT2755675T (pt) 2018-10-11
CN103945861A (zh) 2014-07-23
NZ622174A (en) 2015-12-24
US20200392195A1 (en) 2020-12-17
KR102007054B1 (ko) 2019-08-02
EP2755675A4 (en) 2015-07-08
AU2012308636B2 (en) 2017-08-31
CN103945861B (zh) 2018-06-05
US20240067695A1 (en) 2024-02-29
CA2848204A1 (en) 2013-03-21
WO2013040093A3 (en) 2014-05-08
EP2755675A2 (en) 2014-07-23
WO2013040093A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
ES2687651T3 (es) Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
ZA202007304B (en) Glp-1 receptor agonists and uses thereof
PH12019501360A1 (en) Glp-1 receptor agonists and uses thereof
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
CR11849A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2012002031A1 (es) Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
GT201600263A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
PE20191043A1 (es) Composicion farmaceutica
AR092076A1 (es) Proteinas homodimericas
AR092873A1 (es) Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
CR20120242A (es) Composición farmacéutica que comprende un agonista de glp-1, y metionina
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
DOP2012000133A (es) Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
BR112015023071A2 (pt) conjugados de insulina-incretina
BR112012027545A8 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
NI201000053A (es) Trans-clomifeno para el síndrome metabólico.
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
BR112012015984A2 (pt) composição para melhorar a função cerebral, e, polipeptídeo
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2